SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001140361-22-018856
Filing Date
2022-05-12
Accepted
2022-05-12 16:43:12
Documents
14
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A brhc10037510_10ka.htm   iXBRL 10-K/A 42875
2 EXHIBIT 31.1 brhc10037510_ex31-1.htm EX-31.1 13892
3 EXHIBIT 31.2 brhc10037510_ex31-2.htm EX-31.2 14118
  Complete submission text file 0001140361-22-018856.txt   277014

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA knte-20211231.xsd EX-101.SCH 3928
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE knte-20211231_lab.xml EX-101.LAB 31950
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE knte-20211231_pre.xml EX-101.PRE 22617
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10037510_10ka_htm.xml XML 7298
Mailing Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130
Business Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130 8582994699
Kinnate Biopharma Inc. (Filer) CIK: 0001797768 (see all company filings)

IRS No.: 824566526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39743 | Film No.: 22918559
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences